Login to Your Account



Biogen shares weighed down by 'complex' top-line phase II results

By Michael Fitzhugh
Staff Writer

Tuesday, June 7, 2016

Biogen Inc. shares sank 12.8 percent to close at $252.86 on Tuesday after the company said that opicinumab missed both the primary and secondary efficacy endpoints in the phase II study Synergy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription